The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids

NCT ID: NCT00951912

Last Updated: 2012-10-17

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

165 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many studies showed that soy foods or soy isoflavones can lower the risk of cardiovascular disease (CVD), osteoporosis and some cancers, but few human studies assessed effects of purified isoflavone components (genistein and daidzein) on glucose metabolism. This double-blinded, randomized, placebo-controlled trial will examine the effects of purified genistein and daidzein on glucose metabolism in prediabetic or diabetic women. One hundred and eighty eligible women age 30-70 years(without any treatment of diabetic drugs) will be recruited and randomly allocated into the following three arms: Placebo (10g isolated soy protein, ISP); Genistein (10g ISP + 50mg genistein); Daidzein (10g ISP + 50mg daidzein) per day for 6 mo. Fasting glucose, lipids, insulin, inflammation marks and post-load for glucose and insulin will be determined at 0, 3th, and 6th month. Changes in these indices will be compared among the three groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects were Chinese adult women, age 30-70 year, with an FG concentration ranging from 5.6 to 7.0 mmol/L or 2-h PG concentration ranging from 7.8-11.0 mmol/L or with newly diagnosed diabetes not requiring medication treatment according to a doctor's suggestion or participants did not willing to take medication themselves, and managed their diabetes just with a stable diet and exercise. Women were excluded if they had a history of coronary heart disease, stoke, thyroid disease, severe liver, lung, or gastrointestinal tract diseases; were currently or in the past 8 weeks used hypoglycemic or lipid-lowering or weight-reduction agents; were occurrence of diabetic complications; use of hormone replacement therapy; allergy to soy;were long-term antibiotics users.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

genistein daidzein impaired glucose regulation glucose metabolism lipids metabolism inflammation women

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

10g soy protein isolated powder patch by mouth everyday for 6months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

10g soy protein isolated per day

Daidzein

10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months

Group Type EXPERIMENTAL

Daidzein

Intervention Type DIETARY_SUPPLEMENT

50mg daidzein +10g soy protein isolated per day

Genistein

10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months

Group Type EXPERIMENTAL

Genistein

Intervention Type DIETARY_SUPPLEMENT

50mg genistein +10g soy protein isolated per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

10g soy protein isolated per day

Intervention Type DIETARY_SUPPLEMENT

Daidzein

50mg daidzein +10g soy protein isolated per day

Intervention Type DIETARY_SUPPLEMENT

Genistein

50mg genistein +10g soy protein isolated per day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chinese women aged 30-70 y
* Fasting glucose \>=5.6 mmol/l; post-load glucose \>=7.8 mmol/l

Exclusion Criteria

* Diabetes renal diseases
* Confirmed CVD, chronic liver,kidney diseases,Thyroid disease
* Medications affecting glucose or lipid metabolism
Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese Nutrition Society

UNKNOWN

Sponsor Role collaborator

Danone Institute International

OTHER

Sponsor Role collaborator

Department of Health of Guangdong Province

UNKNOWN

Sponsor Role collaborator

Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

yanbinye

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yan-bin Ye, MD

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-sen University

Yu-ming Chen, PhD

Role: STUDY_DIRECTOR

Sun Yat-sen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital, Sun Yat-sen University

Guangzhou, Guangdong, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

yanbinye

Identifier Type: -

Identifier Source: org_study_id